Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5592648 | 0.89 | MEN1 (0.55) | CA12CA1CA2CA9MEN1 | |
| SCHEMBL3765919 | 0.81 | CA12 (0.59) | CA12CA1CA2CA9MAPT | |
| SCHEMBL3549311 | 0.81 | CA12 (0.59) | CA12CA1CA2CA9MAPT | |
| SCHEMBL5549558 | 0.81 | CA12 (0.59) | CA12CA1CA2CA9MAPT | |
| SCHEMBL7428266 | 0.80 | CA12 (0.54) | CA12CA1CA2CA9MAPT | |
| SCHEMBL6708273 | 0.79 | L3MBTL1 (0.79) | CA12CA1CA2CA9MAPT | |
| SCHEMBL490629 | 0.79 | CA12 (0.58) | CA12CA1CA2CA9MAPT | |
| SCHEMBL20870704 | 0.79 | EPHX2 (0.70) | CA12CA1CA2CA9MAPT | |
| SCHEMBL6521536 | 0.79 | CA12 (0.58) | CA12CA1CA2CA9MAPT | |
| SCHEMBL1310823 | 0.79 | HDAC1 (0.67) | CA12CA1CA2CA9MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1159299-C | Arylalkylpyridzinones | Ĭ��ר���ɷ�����˾ | 2004-07-28 | — | — | CN | disclosed |
| US-6531473-B2 | Phosphodiesterase inhibitor; antiinflammatory agents | MERCK PATENT GMBH (DE) | 2003-03-11 | — | — | US | disclosed |
| EP-0738715-B1 | Arylalkyl-pyridazinones | MERCK PATENT GMBH (DE) | 2003-01-29 | — | — | EP | disclosed |
| US-20020111356-A1 | Arylalkylpyridazinones | MERCK KGAA (DE) | 2002-08-15 | — | — | US | disclosed |
| US-6399611-B1 | 2-(4-ETHOXYCARBONYLAMINOBENZYL)-6-(3,4 -DIMETHOXYPHENYL)-2,3,4, 5-TETRAHYDROPYRIDAZIN-3-ONE OR ALTERNATELY BENZYL SUBSTITUTED COMPOUNDS; PHOSPHODIESTERASE IV AND TUMOUR NECROSIS FACTOR INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2002-06-04 | — | — | US | disclosed |
| EP-0723962-B1 | Arylalkyl-thiadiazinones | MERCK PATENT GMBH (DE) | 2001-07-04 | — | — | EP | disclosed |
| EP-0702013-B1 | Imidazopyridines | MERCK PATENT GMBH (DE) | 2001-06-13 | — | — | EP | disclosed |
| CN-1064962-C | Arylalkyl-thiadiazinones | MERCK PATENT GMBH (DE) | 2001-04-25 | — | — | CN | disclosed |
| US-6037349-A | HAVING ANTAGONISTIC PROPERTIES TOWARDS ANGIOTENSIN II CAN BE USED FOR THE TREATMENT OF HYPERTENSION, ALDOSTERONISM AND CARDIAC INSUFFICIENCY | MERCK PATENT GMBH (DE) | 2000-03-14 | — | — | US | disclosed |
| US-6025354-A | Arylalkyl-thiadiazinones | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2000-02-15 | — | — | US | disclosed |
| CN-1142493-A | Arylalkylpyridzinones | MERCK PATENT GMBH (DE) | 1997-02-12 | — | — | CN | disclosed |
| EP-0738715-A2 | Arylalkyl-pyridazinones | MERCK PATENT GmbH (DE) | 1996-10-23 | — | — | EP | disclosed |
| EP-0723962-A1 | Arylalkyl-thiadiazinones | MERCK PATENT GmbH (DE) | 1996-07-31 | — | — | EP | disclosed |
| EP-0702013-A2 | Imidazopyridines | MERCK PATENT GmbH (DE) | 1996-03-20 | — | — | EP | disclosed |
| US-5438063-A | Hypotensive agents, cardiac insufficiency, increased intraocular pressure, and CNS disorders | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1995-08-01 | — | — | US | disclosed |
| EP-0657454-A1 | Imidazopyridazines being angiotensin II antagonists | MERCK PATENT GmbH (DE) | 1995-06-14 | — | — | EP | disclosed |
| US-5389642-A | Exhibit antagonistic properties toward angiotensin(II); useful for treatment of hypertensioni, aldosteronism, cardiac insufficiency, increased intraocular pressure and disorders of the central nervous system | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1995-02-14 | — | — | US | disclosed |
| EP-0628556-A1 | Imidazopyridines | MERCK PATENT GmbH (DE) | 1994-12-14 | — | — | EP | disclosed |
| EP-0602521-A1 | Imidazopyridines | MERCK PATENT GmbH (DE) | 1994-06-22 | — | — | EP | disclosed |
| EP-0505893-A1 | Imidazopyridines | MERCK PATENT GmbH (DE) | 1992-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111356-A1 | Arylalkylpyridazinones | PDE4A, PDE5A, PDE2A | CA12 4510/4885CA1 3756/4885CA2 975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.